Cargando…

Inflammatory Cytokines and Risk of Ischemic Stroke: A Mendelian Randomization Study

Background: Observational studies have revealed the association between some inflammatory cytokines and the occurrence of ischemic stroke, but the causal relationships remain unclear. Methods: We conducted a two-sample Mendelian randomization (MR) analysis to assess the causal effects of thirty infl...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yalan, Lu, Jun, Wang, Jie, Deng, Peizhi, Meng, Changjiang, Tang, Haibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801801/
https://www.ncbi.nlm.nih.gov/pubmed/35111052
http://dx.doi.org/10.3389/fphar.2021.779899
_version_ 1784642544019177472
author Li, Yalan
Lu, Jun
Wang, Jie
Deng, Peizhi
Meng, Changjiang
Tang, Haibo
author_facet Li, Yalan
Lu, Jun
Wang, Jie
Deng, Peizhi
Meng, Changjiang
Tang, Haibo
author_sort Li, Yalan
collection PubMed
description Background: Observational studies have revealed the association between some inflammatory cytokines and the occurrence of ischemic stroke, but the causal relationships remain unclear. Methods: We conducted a two-sample Mendelian randomization (MR) analysis to assess the causal effects of thirty inflammatory cytokines and the risk of ischemic stroke. For exposure data, we collected genetic variants associated with inflammatory cytokines as instrumental variables (IVs) from a genome-wide association study (GWAS) meta-analysis from Finland (sample size up to 8,293). For the outcome data, we collected summary data of ischemic stroke from a large-scale GWAS meta-analysis involved 17 studies (34,217 cases and 406,111 controls). We further performed a series of sensitivity analyses as validation of primary MR results. Results: According to the primary MR estimations and further sensitivity analyses, we established one robust association after Bonferroni correction: the odds ratio (95% CI) per unit change in genetically increased IL-4 was 0.84 (0.89–0.95) for ischemic stroke. The chemokine MCP3 showed a nominally significant association with ischemic stroke risk (OR: 0.93, 95% CI: 0.88–0.99, unadjusted p < 0.05). There was no evidence of a causal effect of other inflammatory cytokines and the risk of ischemic stroke. Conclusions: Our study suggested that genetically increased IL-4 levels showed a protective effect on the risk of ischemic stroke, which provides important new insights into the potential therapeutic target for preventing ischemic stroke.
format Online
Article
Text
id pubmed-8801801
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88018012022-02-01 Inflammatory Cytokines and Risk of Ischemic Stroke: A Mendelian Randomization Study Li, Yalan Lu, Jun Wang, Jie Deng, Peizhi Meng, Changjiang Tang, Haibo Front Pharmacol Pharmacology Background: Observational studies have revealed the association between some inflammatory cytokines and the occurrence of ischemic stroke, but the causal relationships remain unclear. Methods: We conducted a two-sample Mendelian randomization (MR) analysis to assess the causal effects of thirty inflammatory cytokines and the risk of ischemic stroke. For exposure data, we collected genetic variants associated with inflammatory cytokines as instrumental variables (IVs) from a genome-wide association study (GWAS) meta-analysis from Finland (sample size up to 8,293). For the outcome data, we collected summary data of ischemic stroke from a large-scale GWAS meta-analysis involved 17 studies (34,217 cases and 406,111 controls). We further performed a series of sensitivity analyses as validation of primary MR results. Results: According to the primary MR estimations and further sensitivity analyses, we established one robust association after Bonferroni correction: the odds ratio (95% CI) per unit change in genetically increased IL-4 was 0.84 (0.89–0.95) for ischemic stroke. The chemokine MCP3 showed a nominally significant association with ischemic stroke risk (OR: 0.93, 95% CI: 0.88–0.99, unadjusted p < 0.05). There was no evidence of a causal effect of other inflammatory cytokines and the risk of ischemic stroke. Conclusions: Our study suggested that genetically increased IL-4 levels showed a protective effect on the risk of ischemic stroke, which provides important new insights into the potential therapeutic target for preventing ischemic stroke. Frontiers Media S.A. 2022-01-17 /pmc/articles/PMC8801801/ /pubmed/35111052 http://dx.doi.org/10.3389/fphar.2021.779899 Text en Copyright © 2022 Li, Lu, Wang, Deng, Meng and Tang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Yalan
Lu, Jun
Wang, Jie
Deng, Peizhi
Meng, Changjiang
Tang, Haibo
Inflammatory Cytokines and Risk of Ischemic Stroke: A Mendelian Randomization Study
title Inflammatory Cytokines and Risk of Ischemic Stroke: A Mendelian Randomization Study
title_full Inflammatory Cytokines and Risk of Ischemic Stroke: A Mendelian Randomization Study
title_fullStr Inflammatory Cytokines and Risk of Ischemic Stroke: A Mendelian Randomization Study
title_full_unstemmed Inflammatory Cytokines and Risk of Ischemic Stroke: A Mendelian Randomization Study
title_short Inflammatory Cytokines and Risk of Ischemic Stroke: A Mendelian Randomization Study
title_sort inflammatory cytokines and risk of ischemic stroke: a mendelian randomization study
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801801/
https://www.ncbi.nlm.nih.gov/pubmed/35111052
http://dx.doi.org/10.3389/fphar.2021.779899
work_keys_str_mv AT liyalan inflammatorycytokinesandriskofischemicstrokeamendelianrandomizationstudy
AT lujun inflammatorycytokinesandriskofischemicstrokeamendelianrandomizationstudy
AT wangjie inflammatorycytokinesandriskofischemicstrokeamendelianrandomizationstudy
AT dengpeizhi inflammatorycytokinesandriskofischemicstrokeamendelianrandomizationstudy
AT mengchangjiang inflammatorycytokinesandriskofischemicstrokeamendelianrandomizationstudy
AT tanghaibo inflammatorycytokinesandriskofischemicstrokeamendelianrandomizationstudy